ARCTICZYMES Aktie

 

Stockholm, 6 March 2026: ArcticZymes Technologies ASA (OSE: “AZT”) today hosts its Capital Markets Day 2026 in Stockholm, outlining how the Company is scaling a diversified enzyme platform designed to deliver sustainable growth and long-term value creation. Building on more than 30 years of enzyme expertise, ArcticZymes is positioned to benefit from increasing demand for high-performance enzymes used in molecular diagnostics, research and advanced biomanufacturing. “ArcticZymes is entering its next phase of growth. By strengthening our commercial engine, expanding our enzyme portfolio and...

ArcticZymes Technologies ASA (OSE: "AZT") is pleased to invite investors, analysts, media and other stakeholders to its upcoming Capital Markets Day. The objective of the day is to provide clearer insight into ArcticZymes' position, ambitions, strategic direction and long‑term value creation framework. Date: 6 March 2026 Venue: Smålandsgatan 17, Stockholm (Sweden) / virtually (details below) Time: Doors open at 08:30 Preliminary agenda: · 0830-0900: Registration and coffee · 0900-0915: Introduction · 0915-1200: Capital Markets Day & Q&A · 1200-1230: Lunch and investor...

Tromsø, Norway, February 12, 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported financial results for the fourth quarter and full year 2025, reflecting accelerating sales growth, improved operating leverage and continued penetration in its core business segments. Following a return to growth in 2025, the Company enters 2026 with strengthened commercial momentum and a robust balance sheet. Q4 2025 Highlights · Total revenue: NOK 34.7 million (Q4 2024: NOK 26.4 million), +31% year-on-year · Sales revenue: NOK 34.1 million (Q4 2024: NOK 24.5 million), +39% year-on-year ·...

ArcticZymes Technologies ASA invites investors, analysts and other stakeholders to its Capital Markets Day on 6 March 2026, 09:00–12:00 CET (registration and coffee from 08:30). The event will take place at Nordea's offices, Smålandsgatan 17, Stockholm, Sweden but can also be joined virtually.  Building a Scalable Enzyme Platform  At the Capital Markets Day, management will present how ArcticZymes has completed its commercial transformation and is now focused on scaling its enzyme platform across high-growth biomanufacturing and molecular tool markets.  The session will address:...

The Company will host a virtual Q4 and 12M 2025 presentation for investors, analysts and media at 10:00 CET on Thursday, 12 February, 2026. The presentation will be given by CEO, Michael Akoh, CCO, Paul Blackburn and CFO, Børge Sørvoll. The presentation can be followed as a live webcast from Hegnar TV on https://qcnl.tv/p/XRgPIoZrlRfhnjAmevVbeQ  or www.arcticzymes.com. It will be possible to post questions through the webcast console. The company is also pleased to announce it will host a Capital Markets Day Friday 6th March from 0900-1200, in Stockholm. More information will be...

Tromsø, Norway, November 28th, 2025 - Reference is made to the stock exchange announcement published by ArcticZymes Technologies ASA (the "Company", OSE: AZT) on 25 November 2025 announcing the initiation of a share buyback program pursuant to the authorization granted by the Annual General Meeting held on 27 May 2025. The share buyback program has now been completed. From and including 25 November 2025 to and including 28 November 2025, the Company has purchased a total of 31,365 own shares at an average price of NOK 22.5037 per share. Please see the attached table for further details....

(Tromsø/Oslo, 25 November 2025) ArcticZymes Technologies ASA (OSE:AZT) will today present at DNB Carnegie's Nordic Healthcare Conference 2025 in Oslo. Estimated start of the presentation will be at 09.25 CET Speaker will be CEO, Michael Akoh Please find the presentation enclosed For further information: Børge Sørvoll CFO +47 950 90 187 ir@arcticzymes.com...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Tromsø, Norway, November 6, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the third quarter of 2025, reporting strong topline growth and solid operational performance. Total revenues reached NOK 29.8 million, an increase of 24% year-over-year, driven by robust performance across both Biomanufacturing and Molecular Tools segments. A significant milestone following the end of the quarter was the signing of an exclusive European partnership agreement with Brenntag, expanding ArcticZymes' reach in the biomanufacturing market for advanced therapies. Key...

MUEHLHEIM (dpa-AFX) - Brenntag SE (BNTGF.PK), Wednesday announced an exclusive distribution agreement with ArcticZymes AS on the salt-active nucleases - SAN HQ, SAN-HQ GMP, M-SAN HQ, M-SAN HQ GMP.......

Tromsø, Norway, August 14, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the second quarter of 2025, highlighting progress in the Company's commercial transformation. Total revenues reached NOK 28.9 million, up 5% year-over-year, led by strong 52% growth in the Biomanufacturing segment which contributed NOK 18.1 million. The quarter also marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a product developed in direct response to customer needs. M-SAN HQ GMP enables broader integration into viral vector manufacturing and...

(Tromsø, 04 June 2025) ArcticZymes Technologies ASA (OSE:AZT) will present at Handelsbanken's Small & Mid Cap Seminar 2025 in Stockholm taking place today, 04 June 2025. Estimated start of the presentation will be at 11.20 CET Speaker will be CEO, Michael Akoh Please find the presentation enclosed For further information: Børge Sørvoll CFO +47 950 90 187 ir@arcticzymes.com...

Marit Sjo Lorentzen, VP Operations has on 3 June purchased 3.400 shares in ArcticZymes Technoloiges ASA for NOK 16.00 per share. Following this transaction holds Mrs. Lorentzen 28.731 shares and 135,000 options in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act. For additional information, please contact Børge Sørvoll CFO +4795290187 ir@arcticzymes.com...

Tromsø, Norway, May 28th, 2025 – ArcticZymes Technologies ASA (OSE: AZT), in collaboration with the Austrian Centre of Industrial Biotechnology (acib), has extended their joint research partnership for another three years, focusing on delivering significantly enhanced purification methods for bionanoparticles (BNPs), critical for safer, more effective gene therapies, vaccines, and cancer treatments. The ongoing phase of the project, which began in April 2024, demonstrated that focusing on the removal of chromatin rather than accessible forms of DNA, is essential for improved purification of...

(Tromsø 27. May 2025) The Annual General Meeting of ArcticZymes Technologies ASA (OSE:AZT) was held today, 27. May 2025 as a physical meeting with opportunity for virtual participation. Attached to this announcement are the minutes of the Annual General Meeting in Norwegian and an English translation. All items on the agenda were adopted as proposed. For further information, please contact: Børge Sørvoll CFO +47 952 90187 borge.sorvoll@arcticzymes.com This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act....